The clinical-stage firm revealed that up to 61% of patients with previously treated chronic myeloid leukemia showed a substantial decline in cancer markers during the phase 1 trial. The drug’s safety profile appeared robust, with only 6% of participants discontinuing the regimen due to adverse side effects. Chief Medical Officer Helen Collins described the data as a validation of the treatment's consistency. Following these results, the company reached an agreement with the Food and Drug Administration regarding the specific dosing protocols and patient demographics for the upcoming large-scale phase 3 study. Shares of the company had already doubled year-to-date prior to Thursday’s surge.